Medindia

X

Reportlinker Adds Idiopathic Pulmonary Fibrosis - Pipeline Assessment and Market Forecasts to 2017

Wednesday, July 21, 2010 Press Release J E 4
Advertisement


NEW YORK, July 20 Reportlinker.com announces that a new market research report is available in its catalogue:

Idiopathic Pulmonary Fibrosis - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0240277/Idiopathic-Pulmonary-Fibrosis---Pipeline-Assessment-and-Market-Forecasts-to-2017.html

Idiopathic Pulmonary Fibrosis - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData's pharmaceutical and healthcare report, "Idiopathic Pulmonary Fibrosis - Pipeline Assessment and Market Forecasts to 2017" is an essential source of information and analysis on the global idiopathic pulmonary fibrosis market. The report identifies the key trends shaping and driving the global idiopathic pulmonary fibrosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global idiopathic pulmonary fibrosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

The global Idiopathic Pulmonary Fibrosis (IPF) market was valued at $88m in 2009. It is expected to increase with a compound annual growth rate (CAGR) of 23% from $88m in 2009 to $462m by 2017. Earlier, the IPF market was underserved due to a lack of approved products. In October 2008, the Japanese manufacturer Shionogi received approval for Pirespa in Japan. It is under regulatory review for approval in the US and EU. The expected increase in sales is due to the expected approval of Pirespa in the US and the EU and also the expected launch of Tracleer and Letiaris. Growth in the IPF market is being driven by the sales of Pirespa, off-label drug use and the anticipated approval of Letiaris and Tracleer. Gilead's Letiaris and Actelion's Tracleer are the most anticipated molecules in the IPF market.

Scope

The report provides information on the key driver and challenges of the idiopathic pulmonary fibrosis market. Its Scope includes:

- Annualized global idiopathic pulmonary fibrosis market revenues data from 2001 to 2009, forecast forward for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include enzyme inhibitors, protein inhibitors, endothelin A antagonists, combination therapy, TNF alpha antagonists, platelet aggregation inhibitors, interferon alpha, interleukin inhibitors, immunosuppresants, growth hormone inhibitors, gene therapy, LPA1 receptor antagonists, tumor growth factor inhibitors and NK-1 antagonists.

- Analysis of the current and future market competition in the global idiopathic pulmonary fibrosis market. Key market players covered are Gilead Sciences, Actelion Ltd., Amgen Inc., InterMune Inc. and Amarillo Biosciences.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with idiopathic pulmonary fibrosis therapeutics.

Reasons to buy

The report will enhance your decision making capability in a rapid and time sensitive manner. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global idiopathic pulmonary fibrosis market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global idiopathic pulmonary fibrosis market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain the competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global idiopathic pulmonary fibrosis market landscape? - Identify, understand and capitalize.

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 5

2 Global Idiopathic Pulmonary Fibrosis Market: Market Characterization 6

2.1 Overview 6

2.2 Idiopathic Pulmonary Fibrosis Market Size 6

2.3 Idiopathic Pulmonary Fibrosis Market Forecast and CAGR 6

2.4 Drivers and Barriers for Idiopathic Pulmonary Fibrosis Market 8

2.4.1 Drivers for Idiopathic Pulmonary Fibrosis Market 8

2.4.2 Barriers for Idiopathic Pulmonary Fibrosis Market 9

2.5 Opportunity and Unmet Need 10

2.6 Key Takeaway 11

3 Idiopathic Pulmonary Fibrosis Market: Competitive Assessment 13

3.1 Overview 13

3.2 Strategic Competitor Assessment 13

3.3 Profiles of the Major Therapeutic Class in Idiopathic Pulmonary Fibrosis 14

3.3.1 Overview 14

3.3.2 Immunosuppresants 14

3.3.3 Anti-inflammatory Drugs 15

3.3.4 Antifibrotics 16

3.4 Key Takeaway 18

4 Idiopathic Pulmonary Fibrosis Market: Pipeline Assessment 19

4.1 Overview 19

4.2 Strategic Pipeline Assessment 19

4.2.1 Technology Trends Analytic Framework 19

4.3 Idiopathic Pulmonary Fibrosis Therapeutics - Promising Drugs under Clinical Development 20

4.4 Molecule Profile for Promising Drugs for Idiopathic Pulmonary Fibrosis under Clinical Development 22

4.4.1 Letairis (ambrisentan) 22

4.4.2 Tracleer (bosentan) 23

4.4.3 Enbrel (etanercept) 24

4.4.4 Veldona (Oral interferon alfa) 25

4.5 Idiopathic Pulmonary Fibrosis Therapeutics Market - Clinical Pipeline by Mechanism of Action 26

4.6 Idiopathic Pulmonary Fibrosis Pipeline - Pipeline by Clinical Phases of Development 27

4.6.1 Idiopathic Pulmonary Fibrosis Therapeutics - Phase III Clinical Pipeline 28

4.6.2 Idiopathic Pulmonary Fibrosis Therapeutics - Phase II Clinical Pipeline 29

4.6.3 Idiopathic Pulmonary Fibrosis Therapeutics - Phase I Clinical Pipeline 29

4.6.4 Idiopathic Pulmonary Fibrosis Therapeutics - Preclinical Pipeline 30

4.7 Discontinued / Suspended Drug for Idiopathic Pulmonary Fibrosis 31

4.8 Key Takeaway 31

5 Idiopathic Pulmonary Fibrosis : Implications for Future Market Competition 32

6 Idiopathic Pulmonary Fibrosis Market: Future Players in the Idiopathic Pulmonary Fibrosis Market 34

6.1 Introduction 34

6.2 Gilead Sciences, Inc., California 34

6.2.1 Overview 34

6.2.2 Respiratory Disease Portfolio 36

6.2.3 Idiopathic Pulmonary Fibrosis Product Portfolio 36

6.3 Actelion Ltd. 37

6.3.1 Overview 37

6.3.2 Respiratory Disease Portfolio 38

6.3.3 Idiopathic Pulmonary Fibrosis Product Portfolio 38

6.4 Amgen Inc. 39

6.4.1 Overview 39

6.4.2 Respiratory Disease Portfolio 40

6.4.3 Idiopathic Pulmonary Fibrosis Product Portfolio 40

6.5 InterMune, Inc. 41

6.5.1 Overview 41

6.5.2 Respiratory Disease Portfolio 43

6.6 Amarillo Biosciences 44

6.6.1 Overview 44

6.6.2 Respiratory Disease Portfolio 45

6.6.3 Idiopathic Pulmonary Fibrosis Product Portfolio 46

7 Idiopathic Pulmonary Fibrosis Market: Appendix 47

7.1 Market Definitions 47

7.2 Abbreviations 47

7.3 Research Methodology 49

7.3.1 Coverage 49

7.3.2 Secondary Research 50

7.3.3 Forecasting 50

7.3.4 Primary Research 53

7.3.5 Expert Panel validation 53

7.4 Contact Us 53

7.5 Disclaimer 53

7.6 Sources 54

1.1 List of Tables

Table 1: Idiopathic Pulmonary Fibrosis Therapeutics, Global, Market Revenues ($m), 2001-2009 7

Table 2: Idiopathic Pulmonary Fibrosis Therapeutics, Global, Market Forecast ($m), 2009-2017 8

Table 3: Major Marketed Products Comparison in the Idiopathic Pulmonary Fibrosis Market, 2010 18

Table 4: Idiopathic Pulmonary Fibrosis Therapeutics - Most Promising Drugs Under Clinical Development, 2010 20

Table 5: Idiopathic Pulmonary Fibrosis Therapeutics - Phase III Clinical Pipeline, 2010 28

Table 6: Idiopathic Pulmonary Fibrosis Therapeutics - Phase II Clinical Pipeline, 2010 29

Table 7: Idiopathic Pulmonary Fibrosis Therapeutics - Phase I Clinical Pipeline, 2010 29

Table 8: Idiopathic Pulmonary Fibrosis Therapeutics - Preclinical Pipeline, 2010 30

Table 9: List of Discontinued Drugs for Idiopathic Pulmonary Fibrosis, 2010 31

Table 10: Gilead Sciences, Inc. -Respiratory Pipeline Products, 2010 36

Table 11: Actelion Ltd. -Respiratory Pipeline Products, 2010 38

Table 12: Amgen Inc. - Respiratory Disease Pipeline Products, 2010 40

Table 13: InterMune, Inc- Respiratory Disease Pipeline Products, 2010 43

Table 14: Amarillo Biosciences - Respiratory Disease Pipeline Products, 2010 45

1.2 List of Figures

Figure 1: Idiopathic Pulmonary Fibrosis Therapeutics, Global, Market Revenues ($m), 2001-2009 7

Figure 2: Idiopathic Pulmonary Fibrosis Therapeutics, Global, Market Forecast ($m), 2009-2017 8

Figure 3: Opportunity and Unmet Need in the Idiopathic Pulmonary Fibrosis Market, 2010 11

Figure 4: Strategic Competitor Assessment of the Major Marketed Products for Idiopathic Pulmonary Fibrosis, 2010 14

Figure 5: Technology Trends Analytic Framework of the Idiopathic Pulmonary Fibrosis Pipeline, 2010 19

Figure 6: Technology Trends Analytic Framework of the Idiopathic Pulmonary Fibrosis Pipeline - Description, 2010 20

Figure 7: Idiopathic Pulmonary Fibrosis Therapeutics - Clinical Pipeline by Mechanism of Action, 2010 27

Figure 8: Idiopathic Pulmonary Fibrosis Pipeline by Phase of Clinical Development, 2010 27

Figure 9: Implications for Future Market Competition in the Idiopathic Pulmonary Fibrosis Market, 2010 32

Figure 10: Idiopathic Pulmonary Fibrosis Therapeutics Market - Clinical Pipeline by Company, 2010 34

Figure 11: GlobalData Methodology, 2010 49

Figure 12: GlobalData Market Forecasting Model, 2010 52

Companies mentioned Gilead Sciences, Inc

Actelion Ltd

Amgen Inc

InterMune, Inc

Amarillo Biosciences

To order this report:

Pathology Industry: Idiopathic Pulmonary Fibrosis - Pipeline Assessment and Market Forecasts to 2017

Pathology Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Contact Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Fibrocell Science, Inc. Announces Addition of Dr. ...
S
Codexis to Announce Second Quarter 2010 Financial ...